Anaphylaxis after vaccination is a rare but significant problem because it can be fatal if not treated promptly. However, it is sometimes difficult to distinguish anaphylaxis from other adverse reactions, such as the vagal reflex. Therefore proper diagnosis and identification of the causative factor are critical for the management and prophylaxis of anaphylaxis, as well as the prevention of unnecessary contraindications and unnecessary treatments because of an incorrect diagnosis.
Inactivated influenza vaccines are produced by means of inoculation of influenza strains into embryonated hen eggs. This means that there is a risk of anaphylaxis caused by contaminating egg antigens if these vaccines are administered to patients with egg allergy. However, safe influenza vaccine use, even in pediatric patients with severe egg allergy, has been reported, [1] [2] [3] which suggests that severe allergic reactions to egg-based influenza vaccines are unlikely. The US Advisory Committee on Immunization Practices recommends that influenza vaccination of patients with severe egg allergy should be performed by a physician with experience in the recognition and management of severe allergic conditions based on the fact that occasional cases of anaphylaxis in patients with egg allergy have been reported. 4 Although the egg albumin levels in influenza vaccines should be less than 10 mg/mL according to the World Health Organization standard, 5 the level of egg albumin in vaccines produced in Japan is far less than that standard. 6 In the 2011-2012 influenza season one manufacturer (manufacturer A) in Japan reported a significant increase in the incidence of influenza vaccine-associated anaphylaxis (IVA; approximately 1 in 1.4 million doses in normal years but 1 in 0.4 million doses in 2011), although no fatalities were reported. Most of the patients did not have egg allergy contrary to the common belief that contaminating egg protein in influenza vaccines is the main cause of anaphylaxis.
The incidence was increased only in the population administered the vaccine produced by manufacturer A and not vaccines from other companies. One of the different ingredients in vaccine A compared with the other vaccines was 2-phenoxyethanol (2-PE), which is used as a preservative, whereas the others used thimerosal. We investigated the cause of these IVA cases by collecting samples from patients from all over Japan and found highly increased influenza vaccine antigen-specific IgE antibodies and positive basophil activation in the patients with IVA but not in control subjects.
METHODS Subjects
Study subjects consisted of a patient group and 2 control groups. The patient group contained 19 children who experienced IVA in the 2011-2012 season (IVA group). Although the patients lived in different areas of Japan, we contacted the physicians who reported the anaphylactic events and asked them to collaborate on this study. The physicians then arranged for participation of the patients in the study. The diagnosis of IVA was confirmed based on the Brighton Collaboration case definition of anaphylaxis of levels 1 and 2. 7 We established 2 control groups comprising patients who had undergone influenza vaccination with vaccine A in the same year but had no adverse events. One group consisted of 10 age-matched children with severe egg allergy who were intolerant to eggs at the time of participation in the study and had a history of egg-induced anaphylaxis (egg allergy group [EA group]). The other group consisted of 15 age-matched children with no egg allergy (no egg allergy group [N group], Table I ). The subjects' histories of other allergic diseases were confirmed by the attending physicians.
The study protocol was approved by the Ethics Committee of Mie National Hospital. All samples were collected after written informed consent had been obtained from the parents.
Blood samples
EDTA-containing whole blood was collected from the patients and control subjects. The samples were divided into 2 parts: 1 for basophil activation experiments and 1 for obtaining plasma.
Measurement of specific IgE antibody levels
Levels of specific IgE to whole influenza vaccines and the key vaccine components (ie, hemagglutinin proteins) were measured by means of ELISA, as described below.
The investigated vaccines were 4 inactivated trivalent influenza vaccines that had been produced by 4 virus, and the corresponding hemagglutinin proteins were separately used as antigens in the assay. In addition to the above hemagglutinin proteins that were produced in embryonated hen eggs, cell culture-derived hemagglutinin proteins devoid of egg protein (Kaketsuken, Kumamoto, Japan) were also used. Other vaccine ingredients, such as preservatives and excipients, namely formaldehyde, phenoxyethanol, and thimerosal, were also tested as antigens. All antigens were dissolved (0.1 mg/mL) in carbonate buffer and placed (0.1 mL per well) in wells of the Nunc-Immuno Plate I (Nunc A_S, Roskilde, Denmark) for 1.5 hours at room temperature. After removal of the supernatants, SuperBlock (Pierce, Rockford, Ill) blocking buffer in PBS was added at 0.15 mL per well and incubated overnight at 48C. Each well was then washed with PBS-Tween at 0.2 mL per well, and plasma diluted with SuperBlock blocking buffer (1:5) was added at 0.1 mL per well. The plates were incubated overnight at room temperature. After washing with PBSTween, biotin-conjugated goat anti-human IgE (1:1,000, 0.1 mL per well; Vector Laboratories, Burlingame, Calif) was added and incubated for 1 hour at room temperature. The plates were washed well, and then streptavidinhorseradish peroxidase (1:5000, 0.1 mL per well; Southern Biotechnology, Birmingham, Ala) was added and incubated for 1 hour at room temperature. The plates were washed well and incubated with a substrate, tetramethylbenzidine solution (ICN Biomedicals, Aurora, Ohio), at 0.1 mL per well for 30 minutes under a light shield. The reaction was stopped by adding 1 N HCl at 0.1 mL per well, and the absorbance at 450 nm was measured with LS-PLATE Manager 2001 (Wako, Osaka, Japan).
Plasma specimens from the 3 patients with anaphylaxis with the highest absorbance measurements were pooled and used as a positive control. Cord blood plasma, which did not contain umbilical IgE, was used as a negative control. A titration curve prepared with the serially diluted and pooled positive plasma was used for quantification of specific IgE levels of the samples with arbitrary units (units per milliliter).
Measurement of CD203c expression on basophils
A commercial kit (Allergenicity Kit; Beckman Coulter, Fullerton, Calif) was used for quantification of basophil CD203c expression. The test was performed according to the manufacturer's instructions. Briefly, EDTAcontaining whole blood was incubated with the vaccines and vaccine components at various concentrations for 60 minutes after addition of a sufficient amount of calcium solution to neutralize the chelating capacity of EDTA. Anti-human IgE antibody at 4 mg/mL and PBS served as positive and negative controls, respectively. PC7-conjugated anti-CD3, fluorescein isothiocyanate-conjugated anti-chemoattractant receptor-homologous molecule express on T H 2 lymphocytes (CRTH2), and phycoerythrin-conjugated antiCD203c antibodies were added during the reaction. The samples were then analyzed on an FC500 flow cytometer (Beckman Coulter). Basophils were detected on the basis of forward side scatter characteristics and negative CD3 and positive CRTH2 results. Upregulation of CD203c on basophils was determined by using a threshold that was defined by the fluorescence of unstimulated cells (negative control) and expressed as the CD203c high percentage.
Statistics
Differences in numeric variables were analyzed with the Mann-Whitney U test for unpaired samples and 1-way ANOVA or the Kruskal-Wallis test for more than 2 independent samples, followed by the Dunn multiple comparison test. The x 2 test was used to examine differences in categorical variables.
RESULTS
Demographic data of the subjects Table I summarizes the background characteristics of the patients with IVA and the members of the EA and N control groups. A total of 36 pediatric cases of IVA were reported in the 2011-2012 season in Japan, and 19 patients were investigated in this study. Demographics of the rest of the 17 patients who did not participate in the study were also shown. There were no differences in age (in months) or sex among the 4 groups. Egg allergy was identified in only 21% of the IVA group, and no patients with IVA had a history of anaphylaxis. Fifty-three percent of the patients with IVA had bronchial asthma compared with 100% in the EA group and 33% in the N group. In general, the EA group appeared more allergic than the IVA group.
Influenza vaccine-specific IgE antibody
Levels of influenza-specific IgE were significantly higher in the IVA group than in the N and EA groups (Fig 1) . The antigen used in the ELISA here was the vaccine that showed an increased incidence of IVA (manufacturer A). Vaccine-specific IgE levels in the IVA and N groups were also measured by using the other vaccine products for 2011-2012 from 3 other manufacturers (ie, B, C, and D) and the product for 2010-2011 from manufacturer A. There were no differences in titers between the products (Fig 2) , indicating that the vaccine-specific IgE in the IVA group was specific not only to manufacturer A's vaccine but also to all the influenza vaccines. We then measured specific IgE levels to the hemagglutinin proteins contained in the vaccines (ie, those from A [H1N1], A [H3N2], and B-like viruses propagated in embryonated eggs [e] and cell culture [c]) and found that the patients with IVA had high levels of hemagglutinin-specific IgE (Fig 3) . Excipients used in the vaccines (ie, formaldehyde, 2-PE, and thimerosal) were also used as antigens in the assay, but there was no IgE binding to them (data not shown).
Basophil CD203c expression induced by influenza vaccine
To further investigate the biological significance of influenza vaccine-specific IgE, we examined basophil activation by the vaccines on the basis of CD203c expression. Influenza vaccineinduced expression of CD203c was significantly higher in the IVA group than in the N and EA groups (Fig 4) .
2-PE, which was used as a preservative, was the major different ingredient in manufacturer A's vaccine compared with the others. Thimerosal was used as the preservative by manufacturers B, C, and D. On the basis of the above ELISA results that there was no direct IgE-binding activity for the preservatives, we tested the effects of 2-PE and thimerosal on the vaccine-induced expression levels of CD203c. We used vaccine devoid of both preservatives and added them at the same concentration as the final product. This experiment was planned and performed after the initial basophil activation experiments shown in Fig 4. For that reason, we considered the possibility that basophil reactivity to these antigens might already have decreased if blood sampling was performed too long after the anaphylactic event, and we selected 8 cases for whom less than 3 months had passed since the event.
Thimerosal showed no effect on basophil activation (data not shown), whereas 2-PE significantly enhanced CD203c expression in the higher vaccine dilutions of 1:1000 and 1:3333 (Fig 5) .
Influenza vaccination of 2011-2012 patients with IVA in the 2012-2013 season
One contraindication for influenza vaccination is a history of anaphylaxis caused by any component of the vaccine. However, if influenza vaccine that does not contain phenoxyethanol might be safe, patients can avoid an ''unnecessary'' contraindication and be eligible for vaccination. With approval from the ethics committee and informed consent from the patients, we vaccinated 3 of the patients with IVA in the 2012-2013 season with manufacturer A's 2012-2013 vaccine, which contained thimerosal rather than 2-PE, for 2 vaccines and manufacturer B's vaccine for the third. None of those patients experienced anaphylaxis, but 2 experienced rather extensive local swelling. One of those patients was not administered the second vaccination. The second underwent the second vaccination after premedication with a nonsedating antihistamine, which resulted in reduced swelling. The third patient had a mild cough after the first vaccination, which resolved spontaneously without treatment. He showed no symptoms after the second vaccination (Table II) .
DISCUSSION
After a spike in IVA in 2011 in Japan, we promptly collected blood samples from patients in collaboration with the vaccine manufacturer and attending physicians in all areas of Japan. Our aim was to determine the cause of the increase in this lifethreatening event. We were able to enroll 19 of the patients who had experienced this rare allergic event in 2011. Because IVA has been known to be related to severe egg allergy, we recruited 2 groups of age-matched control subjects who had been administered the same vaccine safely in the 2011 season: one group had severe egg allergy and the other group had no egg allergy. We found that the patients with IVA had increased levels of IgE antibodies to the influenza vaccine components, and their basophils were significantly activated by the vaccine. Only 21% of the patients with IVA had egg allergy, but it was not severe, and they had no history of anaphylaxis. These findings strongly suggest that the IVA events were caused by allergy to some component of the influenza vaccine but not to its egg component.
The egg albumin level of influenza vaccines produced in Japan is less than 0.8 ng/mL, 6 which is much less than the World Health Organization standard. 5 Most inactivated trivalent vaccines distributed in other countries, such as the United States and United Kingdom, also contain very low amounts of egg proteins, 8 and recent reports stated that the vaccines are safe even for most patients with severe egg allergy. [1] [2] [3] However, anaphylaxis after influenza vaccination still occurs, although the incidence is very low. Recently, the Vaccine Adverse Event Reporting System in the United States received reports of 12 cases of allergic reactions after immunization with an egg-free trivalent recombinant hemagglutinin influenza vaccine (RIV3). 9 The patients had a history of allergies (particularly to eggs) or previous reactions to other influenza vaccines, which probably led to their being administered RIV3. All the symptoms reported were immediate-type symptoms, which is consistent with IgE-mediated reactions. Direct identification of the symptom-eliciting IgE was not performed. 9 In the present study we showed that patients with IVA had high levels of hemagglutinin-specific IgE, and their basophils were actually activated by the offending vaccine.
Other vaccine components and excipients have also been reported as possible causes of anaphylaxis. Gelatin, an excipient, was once a major cause of anaphylaxis related to measles and other vaccines. 10, 11 Although it is still used in a yellow fever vaccine, gelatin has been eliminated from other vaccines produced in Japan, and thus the incidence of gelatin-related anaphylaxis has been significantly reduced. 11 The Sabin vaccine, an oral polio vaccine, contains cow's milk protein and was reported to cause an immediate allergic reaction in children with milk allergy. 12 Allergic reactions to yeast-derived hepatitis B vaccine 13, 14 and allergic reactions against the rubber caps of vaccine vials in patients with latex allergy 15 have also been reported. Influenza vaccines do not contain yeast. Our patients with IVA did not report having latex allergy, and they had not experienced allergic reactions with other vaccines in vials with a rubber cap.
The strengths of our study are that, in spite of the low incidence of IVA, we were able to recruit a relatively large number of patients with IVA in the same season, and we were also able to promptly develop the IgE and basophil activation assays. In Japan physicians are required to report all adverse events after vaccination to the government's Pharmaceuticals and Medical Devices Agency. The Pharmaceuticals and Medical Devices Agency then provides vaccine manufacturers the pertinent information (without patient identification) so that they can take measures as quickly as possible. In 2011, manufacturer A realized that the reports of anaphylaxis with their products were very high, about 3-to 5-fold the average for other years. Because we had treated several early cases in our area and had started to investigate the cause, the company helped us to collect samples from physicians from all over Japan who had treated some of those patients with IVA. In the end, more than half of the 16, 17 reported, from the viewpoint of protective immunity, increased IgE antibody levels to influenza virus after vaccination and after infection. Their study cohorts were very small, and they showed no evidence of IgE function, either protective or allergic. In Canada there was a large increase in anaphylactic and allergy-like reactions to the AS03-adjuvanted monovalent pandemic H1N1 vaccine in 2009. 18 The investigators used skin prick tests with full-strength products to identify IgE-mediated reactions, but only 4% of patients and 3% of control subjects had positive responses. They concluded that IgE-mediated allergies to the pandemic vaccine were rare and that the reactions were either coincidental or attributable to other immunologic reactions to the vaccine. 18 We also performed skin prick tests with full-strength vaccine on 3 of our patients with IVA and 10 control subjects and found that all the patients with IVA had positive responses, whereas all the control subjects, including those with egg allergy, had negative responses. Our enrolled patients with IVA lived throughout Japan, some remote from us, and the collaborating physicians could send us blood samples only after obtaining informed consent. Thus we were not able to perform skin tests on all the patients, and we have not presented the findings in the Results section. A major difference between our study and reports from the United States 9 and Canada 18 was the age of the patients. Our patients were mostly male children around 5 years old, whereas the North American patients with anaphylaxis were mainly middle-aged women. The pathogenesis might differ.
It is unclear why only the vaccine product of manufacturer A and not those of other manufacturers caused an increase in IVA events compared with average years. Because 2-PE was the only ingredient different from the other products, we investigated the effect of 2-PE on influenza vaccine-induced basophil activation and found that it enhanced the activation in the higher vaccine dilutions of 1:1000 and 1:3333. 2-PE is thought to be a safe preservative, and it is commonly used in, for example, cosmetics, ophthalmic solutions, and foods. Several cases of contact dermatitis caused by 2-PE have been reported. [19] [20] [21] However, no specific IgE antibody was detected. 21 Although there is a report of anaphylaxis caused by 2-PE, the anaphylaxis was induced by a topical product. 22 Use of 2-PE in vaccine products has gradually increased, replacing thimerosal. 23 No previous report of 2-PE in vaccines as the cause of anaphylaxis have been reported. Here we show the possibility of enhancement of IgE-mediated reactions by 2-PE in vaccine-sensitized subjects, but there have been no reports suggesting this with other types of vaccine containing 2-PE. It might be that an adverse interaction between 2-PE and vaccine components occurs only in the case of influenza vaccines.
In a separate experiment by manufacturer A on the physicochemical properties of the vaccine, it was observed that the particle sizes of the vaccine components increased slightly during incubation with 2-PE, raising the possibility that larger particles might have promoted cross-linking of IgE antibodies (personal communications). Based on the results of our study and their own investigations, manufacturer A stopped producing the 2-PEcontaining influenza vaccine and replaced it with a thimerosalcontaining vaccine for the 2012-2013 season; the incidence of anaphylaxis returned to the historical level.
Shortcomings of the present study are that we did not prove a direct causal relationship between influenza-specific IgE and IVA and that we did not elucidate the detailed mechanisms underlying IVA. However, challenge tests cannot be ethically performed. Our demonstration of influenza vaccine-specific IgE and vaccineinduced basophil activation in patients with IVA might suffice to prove the relationship. We also examined lymphocyte proliferation in response to the vaccine in some of the patients and control subjects but found no differences between the groups (data not shown). Our results of screening for IgG antibodies in the hemagglutinin inhibition test also did not differ between the patients and control subjects (data not shown). Further investigation of other possible immunologic mechanisms might be necessary to understand the pathology of IVA.
In conclusion, for the first time, we clearly demonstrated significantly increased influenza vaccine-specific IgE and vaccine-induced basophil activation in patients with IVA who were included in the IVA spike in 2011-2012 in Japan. The patients were all children (average age, 62 months), mostly male, and with no severe egg allergy. It is noteworthy that phenoxyethanol, which is used as a preservative in the causative influenza vaccine, might have enhanced the allergic reaction. No other risk factors were found, and we believe there is no basis for adding any new contraindications for influenza vaccination at this point. However, clinicians need to be alert to the possible presence of IgE to vaccine components if there is occurrence of a rare immunologic complication of influenza vaccination.
